Protagonist Therapeutics, Inc.

PRTX

N/A

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 1, 2026

14w

Drug Pipeline

Drug Name	Phase	Indication	Designations
Placebo	Phase 3	Polycythemia Vera	-
Open-label rusfertide	Phase 3	Polycythemia Vera	-
PTG-300	Phase 2	Hereditary Hemochromatosis	-
PN-943	Phase 2	Ulcerative Colitis Chronic Moderate	-

Catalyst Timeline

1 upcoming, 0 past

⭐Phase 3Next

Apr 1, 2026Open-label rusfertide

Primary completion for Open-label rusfertide trial (NCT06033586) in Polycythemia Vera

Regulatory Approvals

PRTX News